b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="phenaturepg" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2873498/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873498/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Journal of Biomedical Science" /><meta name="citation_title" content="Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination" /><meta name="citation_authors" content="Chi-Mu Chuang, Archana Monie, Chien-Fu Hung, T-C Wu" /><meta name="citation_date" content="2010" /><meta name="citation_volume" content="17" /><meta name="citation_doi" content="10.1186/1423-0127-17-32" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2873498/?report=abstract" /><meta name="citation_pmid" content="20426849" /><meta name="DC.Title" content="Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="Chi-Mu Chuang" /><meta name="DC.Contributor" content="Archana Monie" /><meta name="DC.Contributor" content="Chien-Fu Hung" /><meta name="DC.Contributor" content="T-C Wu" /><meta name="DC.Date" content="2010" /><meta name="DC.Identifier" content="10.1186/1423-0127-17-32" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination" /><meta property="og:type" content="article" /><meta property="og:description" content="There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873498/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-phenaturepg.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2873498/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2873498/pdf/12929_2010_Article_146.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1A0F6CE9A4031100000000059D059A.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=Nature%20Public%20Health%20Emergency%20Collection[filter]" class="navlink">Nature Public Health Emergency Collection</a></li><li class="accid">PMC2873498</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div class="banner-generic-logo-background inline_block"><div class="banner-journal-publisher-over-image"><div class="banner-journal-name bl-jtitle-phenaturepg">Journal of Biomedical Science</div><div class="banner-publisher-name">Nature Publishing Group</div></div></div></div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">J Biomed Sci</span>. 2010; 17: 32. </span></div><div><span class="fm-vol-iss-date">Published online 2010 Apr 28. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2F1423-0127-17-32" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/1423-0127-17-32</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2873498</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20426849">20426849</a></div></div></div></div><h1 class="content-title">Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Chuang%20CM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849" class="affpopup" co-rid="_co_idm139869043692304" co-class="co-affbox">Chi-Mu Chuang</a>,<sup>1,</sup><sup>5,</sup><sup>6</sup> <a href="/pubmed/?term=Monie%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849" class="affpopup" co-rid="_co_idm139869043676320" co-class="co-affbox">Archana Monie</a>,<sup>1</sup> <a href="/pubmed/?term=Hung%20CF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849" class="affpopup" co-rid="_co_idm139869043673904" co-class="co-affbox">Chien-Fu Hung</a>,<sup>1,</sup><sup>2</sup> and  <a href="/pubmed/?term=Wu%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849" class="affpopup" co-rid="_co_idm139869043670608" co-class="co-affbox">T-C Wu</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>4</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139869043692304"><h3 class="no_margin">Chi-Mu Chuang</h3><p><sup>1</sup>Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><p><sup>5</sup>Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan </p><p><sup>6</sup>School of Medicine, National Yang-Ming University, Taipei, Taiwan </p><div>Find articles by <a href="/pubmed/?term=Chuang%20CM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849">Chi-Mu Chuang</a></div></div><div id="_co_idm139869043676320"><h3 class="no_margin">Archana Monie</h3><p><sup>1</sup>Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><div>Find articles by <a href="/pubmed/?term=Monie%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849">Archana Monie</a></div></div><div id="_co_idm139869043673904"><h3 class="no_margin">Chien-Fu Hung</h3><p><sup>1</sup>Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><p><sup>2</sup>Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><div>Find articles by <a href="/pubmed/?term=Hung%20CF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849">Chien-Fu Hung</a></div></div><div id="_co_idm139869043670608"><h3 class="no_margin">T-C Wu</h3><p><sup>1</sup>Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><p><sup>2</sup>Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><p><sup>3</sup>Department of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><p><sup>4</sup>Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </p><div>Find articles by <a href="/pubmed/?term=Wu%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20426849">T-C Wu</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139869044196848_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139869044196848_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139869044196848_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139869044196848_ai" style="display:none"><div class="fm-affl" lang="en" id="Aff1"><sup>1</sup>Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </div><div class="fm-affl" lang="en" id="Aff2"><sup>2</sup>Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </div><div class="fm-affl" lang="en" id="Aff3"><sup>3</sup>Department of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </div><div class="fm-affl" lang="en" id="Aff4"><sup>4</sup>Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland USA </div><div class="fm-affl" lang="en" id="Aff5"><sup>5</sup>Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan </div><div class="fm-affl" lang="en" id="Aff6"><sup>6</sup>School of Medicine, National Yang-Ming University, Taipei, Taiwan </div><div><span class="fm-affl">Chi-Mu Chuang, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.oohay@gnaujmc" class="oemail">moc.oohay@gnaujmc</a></span>.</div><div><a href="#idm139869044196848aff-info">Contributor Information</a>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139869044196848_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2010 Jan 11; Accepted 2010 Apr 28.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139869044196848_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; Chuang et al; licensee BioMed Central Ltd. 2010</div><div class="license half_rhythm">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2873498/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p1" class="p p-first-last">There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Methods</h3><p id="__p2" class="p p-first-last">In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to generate E7-specific immune responses and antitumor effects in tumor-bearing mice.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Results</h3><p id="__p3" class="p p-first-last">We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">Conclusions</h3><p id="__p4" class="p p-first-last">Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The current study has significant implications for future clinical translation.</p></div><div id="__sec5" class="sec sec-last"><h3 id="__sec5title">Electronic supplementary material</h3><p id="__p5" class="p p-first-last">The online version of this article (doi:10.1186/1423-0127-17-32) contains supplementary material, which is available to authorized users.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Imiquimod, Cell Immune Response, Taipei Veteran General Hospital, Clodronate Liposome, Topical Imiquimod</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Background</h2><p id="__p6" class="p p-first">Advanced stage cancers are difficult to control using conventional therapies such as chemotherapy, surgery and radiation. Therefore, new innovative therapies are urgently required in order to combat the high mortality and morbidity associated with cancers. Antigen-specific immunotherapy has emerged as an attractive approach for the treatment of cancers since it has the ability to specifically eradicate systemic tumors and control metastases without damaging normal cells. For example, in a recent study, immunotherapy using synthetic long peptide vaccine derived from human papillomavirus type 16 (HPV-16) E6 and E7 antigens has led to significant clinical responses in patients with precancerous lesions of gynecological malignancies [<a href="#CR1" rid="CR1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394816">1</a>].</p><p id="__p7">DNA vaccination has become a potentially promising approach for antigen-specific immunotherapy due to its safety, stability and ease of preparation (for review, see [<a href="#CR2" rid="CR2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394811">2</a>, <a href="#CR3" rid="CR3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394819">3</a>]). We have previously developed several innovative strategies to enhance DNA vaccine potency by directly targeting the DNA into the dendritic cells (DCs) in vivo via gene gun as well as by modifying the properties of antigen-expressing DCs (for review see [<a href="#CR4" rid="CR4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394831">4</a>, <a href="#CR5" rid="CR5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394835">5</a>]).</p><p id="__p8">One of the strategies to enhance DNA vaccine potency uses intracellular targeting strategies to enhance MHC class I antigen presentation and processing in DCs. Previously, we have studied the linkage of calreticulin (CRT), a Ca<sup>2+</sup>-binding protein located in the endoplasmic reticulum (ER) (for review, see [<a href="#CR6" rid="CR6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394826">6</a>]) to several antigens, including human papillomavirus type-16 (HPV-16) E7 [<a href="#CR7" rid="CR7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394837">7</a>, <a href="#CR8" rid="CR8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394834">8</a>], E6 [<a href="#CR9" rid="CR9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394820">9</a>], and nucleocapsid protein of severe acute respiratory syndrome coronavirus [<a href="#CR10" rid="CR10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394841">10</a>]. Intradermal administration of DNA encoding CRT linked to any of these target antigens led to a significant increase in the antigen-specific CD8+ T cell immune responses and impressive antitumor effects in vaccinated mice. Thus, CRT has been shown to be highly potent in enhancing the antigen-specific immune responses and antitumor effects generated by DNA vaccination in several preclinical models.</p><p id="__p9">Another important innovative cancer therapy involves the employment of immunomodulatory agents such as imiquimod (for reviews see [<a href="#CR11" rid="CR11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394812">11</a>, <a href="#CR12" rid="CR12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394832">12</a>]). The exact mechanism of action in which imiquimod and its analogs activate the immune system is still under active investigation. Nevertheless, it is known that imiquimod activates immune cells through the toll-like receptor 7 (TLR7), commonly involved in pathogen recognition, on the cell surface [<a href="#CR13" rid="CR13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394824">13</a>, <a href="#CR14" rid="CR14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394814">14</a>]. Cells activated by imiquimod via TLR-7 secrete cytokines such as IFN-&#x003b1;, IL-6 and TNF-&#x003b1; [<a href="#CR15" rid="CR15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394818">15</a>]. There is evidence that imiquimod, when applied to skin, can lead to the activation of Langerhans cells, which subsequently migrates to local lymph nodes to activate the adaptive immune system [<a href="#CR16" rid="CR16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394838">16</a>]. Other cell types activated by imiquimod include NK cells, macrophages and B-lymphocytes [<a href="#CR16" rid="CR16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394822">16</a>].</p><p id="__p10" class="p p-last">In the current study, we hypothesize that the combination of the DNA vaccine encoding CRT linked to HPV-16 E7 (CRT/E7) with topical application of imiquimod at the site of the tumor will lead to increased infiltration of effectior immune cells at the site of the tumor, resulting in enhanced antitumor effects against E7-expressing tumors in a preclinical model. We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to decrease in the number of myeloid-derived suppressor cells (MDSCs) but not T regulatory cells in the tumor microenvironment of tumor-bearing mice. Treatment with CRT/E7 DNA in combination with imiquimod was also found to lead to an enhancement in the E7-specific CD8+ T cell immune responses in tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Furthermore, macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod. The clinical implications of the current study are discussed.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Methods</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Mice and cell line</h3><p id="__p11" class="p p-first">Female C57BL/6 mice (H-2K<sup>b</sup> and I-A<sup>b</sup>), 5 to 6 wks of age, were purchased from the National Cancer Institute. All of the mice were maintained under specific pathogen-free conditions in the animal facility at Johns Hopkins Hospital or Taipei Veterans General Hospital. Animals were used in compliance with institutional animal health care regulations, and all animal experimental procedures were approved by the Johns Hopkins Institutional Animal Care and Use Committee and Taipei Veterans General Hospital Experimental Animal Center.</p><p id="__p12" class="p p-last">The production and maintenance of TC-1 cells have been described previously [<a href="#CR17" rid="CR17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394813">17</a>]. TC-1 cells were grown in RPMI 1640, supplemented with 10% (v/v) fetal bovine serum, 50 units/mL penicillin/streptomycin, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 2 mmol/L nonessential amino acids, and 0.4 mg/mL G418 at 37&#x000b0;C with 5% CO2. The TC-1 cells have been tested and shown to be free of mycoplasma and other contamination.</p></div><div id="Sec4" class="sec"><h3 id="Sec4title">Plasmid DNA constructs</h3><p id="__p13" class="p p-first-last">The generation of recombinant plasmid pcDNA3-CRT/E7 has been described previously [<a href="#CR7" rid="CR7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394840">7</a>]. The accuracy of the DNA construct was confirmed by DNA sequencing. For the gene gun-mediated intradermal vaccination, 2 &#x003bc;g/mouse of recombinant plasmid DNA were delivered to the shaved abdominal region of C57BL/6 mice using a helium-driven gene gun (Bio-Rad) with a previously described protocol [<a href="#CR18" rid="CR18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394828">18</a>].</p></div><div id="Sec5" class="sec"><h3 id="Sec5title">Flow cytometry analysis</h3><p id="__p14" class="p p-first">For characterization of regulatory T cells and MDSC in tumor microenvironment, C57BL/6 mice were divided into four groups (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined group). All mice were inoculated with TC-1 cells (5 &#x000d7; 10<sup>4</sup>/mouse) s.c. over right leg at d0. For the untreated group, mice were regularly followed after TC-1 implantation without specific treatment. For the imiquimod group, each mouse received topical imiquimod (50 mg/mouse) at the site of the tumor every two days (begun at d6 for a total of 6 treatments). For CRT/E7 alone group, each mouse was vaccinated with pcDNA3-CRT/E7 2 &#x003bc;g via gene gun at d9, d13, and d17. For the combined treatment group, each mouse received the same treatment schedule as for each monotherapy alone group. Tumors were harvested at d24 for flow cytometric analysis. Tumor cells were either stained with PE-conjugated anti-CD4 (L3T4) and FITC-conjugated anti-CD25 (PC61) mAbs for quantification of regulatory T cells, or stained with stained with PE-conjugated anti-CD11b (M1/70) and FITC-conjugated anti-Gr-1 (RB6-8C5) mAbs for quantification of MDSC.</p><p id="__p15">For characterization of E7-specific CD8<sup>+</sup> T cells in tumor microenvironment, C57BL/6 mice were divided into four groups (untreated, imiquimod alone, CRT/E7 alone, and combined group). All mice were inoculated with TC-1 cells (5 &#x000d7; 10<sup>4</sup>/mouse) s.c. over right leg at d0. For the untreated group, mice were regularly followed after TC-1 implantation without specific treatment. For the imiquimod group, each mouse received topical imiquimod (50 mg/mouse) at the site of the tumor every two days (begun at d6 for a total of 6 treatments). For CRT/E7 alone group, each mouse was vaccinated with pcDNA3-CRT/E7 2 &#x003bc;g via gene gun at d9, d13, and d17. For the combined treatment group, each mouse received the same treatment schedule as for each monotherapy alone group. Tumors were harvested at d24 for immune response analysis. Before intracellular cytokine staining, pooled tumors from each treatment group were separately incubated for 16 h with the H2-D<sup>b</sup>-restricted CTL epitope (aa 49-57) (1.0 &#x003bc;mol/L). Cells were then harvested and stained for CD8 and IFN-&#x003b3; using previously described standard protocols [<a href="#CR19" rid="CR19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394815">19</a>]. Samples were analyzed on a FACSCalibur flow cytometer using CellQuest software. All of the analyses shown were carried out on a gated lymphocyte population.</p><p id="__p16" class="p p-last">As for evaluation of change of various immune effectors in tumor microenvironment after imiquimod and CRT/E7 treatment, mice were divided into two groups (5/group: vehicle treated or imiquimod treated), and were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) at d0. Each mouse received topical vehicle cream or imiquimod (50 mg/mouse) every two days initiated at d6 for a total of 6 times. Tumors were harvested 6 hours after last treatment. Tumor cells were then made into single cell suspension, washed once in FACScan buffer, and stained with surface markers for various innate and adaptive effectors including PE-conjugated anti-CD4 (L3T4), PE-conjugated anti-CD8 (53-6.7), FITC-conjugated anti-GR-1 (RB6-8C5), PE-conjugated anti-CD19 (1D3), PE-conjugated anti-NK1.1 (PK136), and PE-Cy5-conjugated anti-F4/80 (BM8). Cells were subjected to flow cytometry analysis gated on lymphocyte population.</p></div><div id="Sec6" class="sec"><h3 id="Sec6title">In vivo evaluation of the antitumor effects generated by combined treatment</h3><p id="__p17" class="p p-first-last">In order to evaluate monotherapy alone or combined treatment for the inhibition of TC-1 tumor growth, we designed a two-step experiment. For the first-step experiment, we evaluated the anti-tumor effects of imiquimod alone therapy. Mice were divided into 2 groups (4/group, untreated or imiquimod treated), which were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) subcutaneously at d0. Mice were then left untreated or treated with imiquimod (50 mg/mouse) at the site of the tumor every two days initiated at d6 for a total of 6 treatments. Mice were euthanized at d21 and tumors were harvested and photographed for tumor size comparison. After having proved that imiquimod was effective as a single agent, we proceeded with the second-step experiment. Mice were divided into four groups (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined group). All mice were inoculated with TC-1 cells (5 &#x000d7; 10<sup>4</sup>/mouse) s.c. over right leg at d0. For the untreated group, mice were regularly followed for tumor growth after TC-1 implantation without specific treatment. For the imiquimod group, each mouse received topical imiquimod (50 mg/mouse) at the site of the tumor every two days (began at d6 for a total of 6 treatments). For CRT/E7 alone group, each mouse was vaccinated with pcDNA3-CRT/E7 2 &#x003bc;g via gene gun at d9, d13, and d17. For the combined treatment group, each mouse received the same treatment schedule as for each monotherapy alone group. Tumor sizes in the mice were monitored and measured every 3-4 days using digital calipers.</p></div><div id="Sec7" class="sec"><h3 id="Sec7title">In vivo antibody depletion experiments</h3><p id="__p18" class="p p-first-last">In order to identify the subset of lymphocytes that were important for anti-tumor effects of combined treatments of imiquimod and pcDNA3-CRT/E7 DNA vaccine, mice were divided into 4 groups (combined treatments without depletion, combined treatments with depletion of neutrophils, combined treatments with depletion of NK1.1+ cells, and combined treatments with depletion of macrophages) using methods similar to what we have described previously [<a href="#CR17" rid="CR17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394823">17</a>]. All mice were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) at d0, and were then treated with imiquimod (at d2, d4, d6, d8, d10, and d12) and pcDNA-CRT/E7 2 &#x003bc;g (d5 and d12). Mice were either undepleted or depleted of macrophages (using clodronate liposomes), NK1.1+ cells (using anti-mouse NK1.1 mAbs, PK136), or neutrophils (using anti-mouse Gr-1 mAbs, RB6-8C5), one day before and 3 days after TC-1 implantation and thereafter once per week until the end of follow-up.</p></div><div id="Sec8" class="sec sec-last"><h3 id="Sec8title">Statistical analysis</h3><p id="__p19" class="p p-first-last">All data expressed as mean &#x000b1; standard deviation (S.D.) are representative of at least two different experiments. Comparisons between individual data points for tumor sizes were made using a Student\'s <em>t</em>-test or repeated measure ANOVA (analysis of variance) test. Differences in survival between experimental groups were analyzed using the log-rank test. Tumor sizes were calculated using the following equation: (tumor length&#x000d7;width&#x000d7;height)/2. Death of mouse was arbitrarily defined as tumor diameter greater than 2 cm.</p></div></div><div id="Sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec9title">Results</h2><div id="Sec10" class="sec sec-first"><h3 id="Sec10title">Treatment with CRT/E7 DNA in combination with imiquimod leads to decrease in the number of myeloid-derived suppressor cells but not CD4+CD25+ T cells in the tumor microenvironment of tumor-bearing mice</h3><p id="__p20" class="p p-first-last">In order to determine the number of CD4+CD25+ T cells (which are mainly comprised of T regulatory cells) and myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice treated with CRT/E7 DNA with imiquimod, we inoculated C57BL/6 mice with TC-1 cells on d0 and treated them with or without topical imiquimod (50 mg/mouse) every two days starting from d6 for a total of 6 treatments). Mice were then vaccinated with CRT/E7 DNA via gene gun on d9, d13, and d17. Untreated mice were used as controls. Tumors were harvested on d24 and characterized for the presence of T regulatory cells and myeloid-derived suppressor cells by flow cytometry analysis. As shown in Figure <a href="/pmc/articles/PMC2873498/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1,</span></span><span>1</span></a>, mice treated with CRT/E7 DNA in combination with imiquimod demonstrated significantly lower numbers of myeloid-derived suppressor cells compared to the other treated mice. In comparison, there was no significant difference in the number of CD4+CD25+ T cells in mice treated with CRT/E7 DNA in combination with imiquimod compared to any of the other groups. Thus, our data indicate that treatment with imiquimod in combination with DNA vaccination can reduce the number of myeloid-derived suppressor cells in the tumor microenvironment of treated mice.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC2873498/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139868973588768" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig1_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig1_HTML.jpg" src="/pmc/articles/PMC2873498/bin/12929_2010_Article_146_Fig1_HTML.jpg" /></div><div id="largeobj_idm139868973588768" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2873498/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC2873498/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p21"><strong>Characterization of the T regulatory cells and myeloid-derived suppressor cells (MDSC) in the tumor microenvironment following vaccination with CRT/E7 DNA with or without imiquimod in tumor-bearing mice</strong>. C57BL/6 mice were divided into four groups (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined group). All mice were inoculated with TC-1 cells (5 &#x000d7; 10<sup>4</sup>/mouse) s.c. over right leg at d0. For the untreated group, mice were regularly followed after TC-1 implantation without specific treatment. For the imiquimod group, each mouse received topical imiquimod (50 mg/mouse) every two days (began at d6 for a total of 6 treatments). For CRT/E7 alone group, each mouse was vaccinated with 2 &#x003bc;g of pcDNA3-CRT/E7 DNA via gene gun at d9, d13, and d17. For the combined treatment group, each mouse received the same treatment schedule as for each monotherapy alone group. Tumors were harvested at d24 for flow cytometric analysis. Tumor cells were either stained with PE-conjugated anti-CD4 (L3T4) and FITC-conjugated anti-CD25 (PC61) mAbs <strong>(A &#x00026; B)</strong> or with PE-conjugated anti-CD11b (M1/70) and FITC-conjugated anti-Gr-1 (RB6-8C5) mAbs <strong>(C &#x00026; D)</strong>. Plots were gated on lymphocyte population. <strong>A)</strong> Representative flow cytometry data demonstrating the percentage of CD4+CD25+ cells. <strong>B)</strong> Bar graph representing the percentage of Tregs among the tumor-infiltrating lymphocytes. <strong>C)</strong> Representative flow cytometry data demonstrating the percentage of CD11b+Gr-1+ cells. <strong>D)</strong> Bar graph representing the percentage of Tregs among the tumor-infiltrating lymphocytes. C denotes untreated group, and I denotes imiquimod treated group. Representative data from one of three independent experiments are shown. *, P &#x0003c; 0.05; **, P &#x0003c; 0.01.</p></div></div></div></div><div id="Sec11" class="sec"><h3 id="Sec11title">Treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses in tumor-bearing mice</h3><p id="__p22" class="p p-first-last">In order to determine the E7-specific immune responses in tumor-bearing mice vaccinated with CRT/E7 DNA with imiquimod, we inoculated C57BL/6 mice with TC-1 cells on d0 and treated them with CRT/E7 DNA vaccine and/or imiquimod as described in Figure <a href="/pmc/articles/PMC2873498/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1.</span></span><span>1</span></a>. Splenocytes from tumor-bearing mice were harvested at d24 and characterized for the E7-specific CD8+ T cell immune responses by intracellular cytokine staining followed by flow cytometry analysis. As shown in Figure <a href="/pmc/articles/PMC2873498/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2,</span></span><span>2</span></a>, mice treated with CRT/E7 DNA in combination with topical application of imiquimod demonstrated significantly higher numbers of E7-specific CD8+ T cells compared to mice treated with CRT/E7 alone. Thus, our data indicate that treatment with imiquimod in combination with DNA vaccination can significantly enhance the E7-specific CD8+ T cell immune responses in treated mice.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC2873498/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139868973577296" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig2_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig2_HTML.jpg" src="/pmc/articles/PMC2873498/bin/12929_2010_Article_146_Fig2_HTML.jpg" /></div><div id="largeobj_idm139868973577296" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2873498/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC2873498/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p23"><strong>Characterization of the E7-specific CD8+ T cell immune responses following vaccination with CRT/E7 DNA with or without imiquimod in tumor-bearing mice</strong>. C57BL/6 mice were divided into four groups (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined group). All mice were inoculated with TC-1 cells (1 &#x000d7; 10<sup>4</sup>/mouse) s.c. over right leg at d0. Treatment schedules were the same as in Figure 1. Splenocytes from tumor-bearing mice were harvested at d24 for immune response analysis, stimulated with E7 epitope (aa49-57), and stained for both CD8 and intracellular interferon-&#x003b3; (IFN-&#x003b3;). <strong>A)</strong> Representative flow cytometry data demonstrating the percentage of CD8<sup>+</sup>IFN-&#x003b3;<sup>+</sup> T cells. The numbers of CD8<sup>+</sup> IFN-&#x003b3;<sup>+</sup> double positive T cells are indicated in the upper right hand corner of each representative dot plot. <strong>B)</strong> Bar graph representing the number of E7-specific CD8+ T cells/3 &#x000d7; 10<sup>5</sup> splenocytes (*, p &#x0003c; 0.05). Representative data from one of three independent experiments are shown.</p></div></div></div></div><div id="Sec12" class="sec"><h3 id="Sec12title">Treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice</h3><p id="__p24" class="p p-first-last">In order to determine the therapeutic antitumor effects generated in tumor-bearing mice vaccinated with CRT/E7 DNA with imiquimod, we inoculated C57BL/6 mice with TC-1 cells on d0 and treated them with CRT/E7 DNA vaccine and/or topical application of imiquimod as described in Figure <a href="/pmc/articles/PMC2873498/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1.</span></span><span>1</span></a>. Tumor growth was monitored over time. As shown in Figure <a href="/pmc/articles/PMC2873498/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3A,</span></span><span>3A</span></a>, mice treated with CRT/E7 DNA in combination with imiquimod demonstrated significantly lower tumor size over time compared to mice treated with CRT/E7 alone. Furthermore, mice treated with CRT/E7 alone or imiquimod alone demonstrated significantly lower tumor volumes compared to the mice without treatment (control). In addition, mice treated with CRT/E7 DNA in combination with topical application of imiquimod demonstrated significantly prolonged survival compared to mice treated with CRT/E7 alone (Figure <a href="/pmc/articles/PMC2873498/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3B).</span></span><span>3B</span></a>). Thus, our data indicate that topical treatment with imiquimod in combination with therapeutic HPV DNA vaccination can enhance the therapeutic antitumor effects against TC-1 tumors in treated mice.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC2873498/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139868972467424" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig3_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig3_HTML.jpg" src="/pmc/articles/PMC2873498/bin/12929_2010_Article_146_Fig3_HTML.jpg" /></div><div id="largeobj_idm139868972467424" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2873498/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC2873498/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p25"><strong>Characterization of the therapeutic antitumor effects generated by treatment with E7-CRT in combination with imiquimod in tumor-bearing mice</strong>. C57BL/6 mice (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined group) were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) at d0. Treatment schedules were the same as described in Figure 1. Tumor growth was monitored over time. <strong>A)</strong> Line graph depicting the tumor sizes in tumor-bearing mice treated with the different regimens. (*, p &#x0003c; .05) <strong>B)</strong> Kaplan-Meier survival curve of the mice treated with the various regimens (*, p &#x0003c; 0.05, compared between CRT/E7 alone and the combined group). Representative data from one of three independent experiments are shown.</p></div></div></div></div><div id="Sec13" class="sec"><h3 id="Sec13title">Treatment with imiquimod leads to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment</h3><p id="__p26" class="p p-first-last">In order to determine the key immune cells in the tumor microenvironment that were upregulated following imiquimod treatment, C57BL/6 mice were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) at d0 and divided into two groups (5/group: vehicle treated or imiquimod treated). Each mouse received topical vehicle cream or imiquimod every two days initiated at d6 for a total of 6 times. Tumors were harvested 6 hours after last imiquimod treatment. Tumor cells were then made into single cell suspension and analyzed for the presence of various immune cell markers by flow cytometry analysis. As shown in Figure <a href="/pmc/articles/PMC2873498/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4,</span></span><span>4</span></a>, mice treated with topical application of imiquimod demonstrated significantly higher number of NK1.1+ cells, which includes both NK cells as well as NKT cells, and F4/80+ inflammatory cells in the tumor microenvironment compared to mice treated with the vehicle. Thus, our data indicate that imiquimod treatment leads to the upregulation of NK1.1+ cells and F4/80+ inflammatory cells in the tumor microenvironment.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig4" co-legend-rid="lgnd_Fig4"><a href="/pmc/articles/PMC2873498/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139868972458976" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig4_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig4_HTML.jpg" src="/pmc/articles/PMC2873498/bin/12929_2010_Article_146_Fig4_HTML.jpg" /></div><div id="largeobj_idm139868972458976" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2873498/figure/Fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig4"><div><a class="figpopup" href="/pmc/articles/PMC2873498/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4">Figure 4</a></div><!--caption a7--><div class="caption"><p id="__p27"><strong>Characterization of the levels of various immune cells in the tumor microenvironment following treatment with imiquimod</strong>. C57BL/6 mice were divided into two groups (5/group: vehicle treated or imiquimod treated) and were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) at d0. Each mouse received topical vehicle cream or imiquimod (50 mg/mouse) every two days initiated at d6 for a total of 6 times. Tumors were harvested 6 hours after last imiquimod treatment. Tumor cells were then made into single cell suspension, washed once in FACScan buffer, and stained with surface markers for various innate and adaptive effectors including PE-conjugated anti-CD4 (L3T4), PE-conjugated anti-CD8 (53-6.7), FITC-conjugated anti-GR-1 (RB6-8C5), PE-conjugated anti-CD19 (1D3), PE-conjugated anti-NK1.1 (PK136), and PE-Cy5-conjugated anti-F4/80 (BM8). Cells were subjected to flow cytometric analysis gated on lymphocyte population (*, p &#x0003c; 0.05, imiquimod versus vehicle). Representative data from one of three independent experiments are shown.</p></div></div></div></div><div id="Sec14" class="sec sec-last"><h3 id="Sec14title">Macrophages and NK1.1+ cells play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod</h3><p id="__p28" class="p p-first-last">In order to determine the immune cells that play an important role in the antitumor effects mediated by CRT/E7 DNA vaccination followed by imiquimod treatment, we performed an in vivo depletion experiment. C57BL/6 mice were divided into 4 groups (5/group). All mice were implanted subcutaneously with TC-1 at d0, and were then treated with imiquimod and CRT/E7 DNA vaccine as described. Mice were either depleted of macrophages (using clodronate liposomes), NK1.1+ cells (using anti-mouse NK 1.1 mAbs, PK136), or neutrophils (using anti-mouse Gr-1 mAbs, RB6-8C5), one day before and 3 days after TC-1 implantation and thereafter once per week until the end of follow-up. Undepleted mice were used as controls. As shown in Figure <a href="/pmc/articles/PMC2873498/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5,</span></span><span>5</span></a>, treated mice depleted of macrophages or NK1.1+ cells demonstrated significant increase in tumor growth compared to undepleted mice or mice depleted of neutrophils. Thus, our data indicate that macrophages and NK1.1+ cells play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig5" co-legend-rid="lgnd_Fig5"><a href="/pmc/articles/PMC2873498/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139868972451184" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig5_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12929_2010_Article_146_Fig5_HTML.jpg" src="/pmc/articles/PMC2873498/bin/12929_2010_Article_146_Fig5_HTML.jpg" /></div><div id="largeobj_idm139868972451184" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2873498/figure/Fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig5"><div><a class="figpopup" href="/pmc/articles/PMC2873498/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5">Figure 5</a></div><!--caption a7--><div class="caption"><p id="__p29"><strong>In vivo depletion experiment</strong>. C57BL/6 mice were divided into 4 groups (5/group). All mice were implanted with TC-1 (5 &#x000d7; 10<sup>4</sup>/mouse) at d0, and were then treated with imiquimod (at d2, d4, d6, d8, d10, and d12) and pcDNA-CRT/E7 2 &#x003bc;g (d5 and d12). Mice were either depleted of macrophages (using clodronate liposomes), NK1.1+ cells (using anti-mouse NK 1.1 mAbs, PK136), or neutrophils (using anti-mouse Gr-1 mAbs, RB6-8C5), one day before and 3 days after TC-1 implantation and thereafter once per week until the end of follow-up. Undepleted mice were used as controls. Line graph depicting the tumor sizes in tumor-bearing mice treated with the different regimens. Representative data from one of three independent experiments are shown.</p></div></div></div></div></div><div id="Sec15" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec15title">Discussion</h2><p id="__p30" class="p p-first">In the current study, we observed that treatment with CRT/E7 DNA in combination with imiquimod leads to decrease in the number of myeloid-derived suppressor cells but not CD4+CD25+ T cells in the tumor microenvironment of tumor-bearing mice. Treatment with CRT/E7 DNA in combination with imiquimod was also found to lead to an enhancement in the E7-specific CD8+ T cell immune responses and improved antitumor effects and prolonged survival in treated mice. Macrophages and <strong>NK1.1</strong>+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod. Our data is quite consistent with the recent clinical trials using therapeutic HPV vaccines in conjunction with imiquimod in patients with vulvar intraepithelial neoplasia. In that study, treatment with imiquimod and vaccination led to clinical responses in some of the patients, with a significant increase local infiltration of CD8+ and CD4+ T cells in the lesions of these patients [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394817">20</a>].</p><p id="__p31">In our study, we have observed that depletion of macrophages in TC-1 tumor-bearing mice treated with imiquimod and CRT/E7 DNA vaccines led to the loss of antitumor effect, suggesting the importance of macrophages in the antitumor effect generated by imiquimod in combination with the DNA vaccine (Figure <a href="/pmc/articles/PMC2873498/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure5).</span></span><span>5</span></a>). Tumor-bearing mice treated with imiquimod also showed a significant increase in the number of F4/80+ macrophages in the tumor microenvironment (Figure <a href="/pmc/articles/PMC2873498/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4).</span></span><span>4</span></a>). Taken together, these data suggest that the combination of CRT/E7 DNA vaccination with imiquimod treatment may result in an increase in M1 macrophages in the tumor, which can contribute to the antitumor effect (for reviews see [<a href="#CR21" rid="CR21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394833">21</a>, <a href="#CR22" rid="CR22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394827">22</a>]) It has been shown that TC-1 tumors contain significant number of M2 macrophages, that lead to suppression of antitumor T-cell response, thus facilitating tumor growth [<a href="#CR23" rid="CR23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394830">23</a>]. Thus, treatment of TC-1 tumors with imiquimod and the CRT/E7 DNA vaccine may result in a switch from immunosuppressive M2 macrophage phenotype to the inflammatory M1 phenotype.</p><p id="__p32">We showed that treatment with imiquimod leads to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment (Figure <a href="/pmc/articles/PMC2873498/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4).</span></span><span>4</span></a>). Furthermore, our antibody depletion experiments indicated that NK1.1+ cells are essential for the observed antitumor effects (Figure <a href="/pmc/articles/PMC2873498/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure5).</span></span><span>5</span></a>). NK cells have been shown to express TLR7 and imiquimod-mediated activation of NK cells through TLR7 may result in IFN-&#x003b3; production [<a href="#CR24" rid="CR24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394821">24</a>]. Thus, it is likely that not only can NK cells directly lead to cytotoxic effects, but NK cells can also lead to increased expression of IFN-&#x003b3; which may lead to upregulation of MHC class I, which may render tumor cells more susceptible to killing by CD8+ T cells.</p><p id="__p33">We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to a reduction in the number of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment of tumor-bearing mice (Figure <a href="/pmc/articles/PMC2873498/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1).</span></span><span>1</span></a>). It has been shown that myeloid-derived suppressor cells play an important immunosuppressive role in the tumor microenvironment (for reviews, see [<a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394825">25</a>&#x02013;<a href="#CR27" rid="CR27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394829">27</a>]). The reduction in MDSCs may potentially lead to improved antigen-specific CD8+ T cell immune responses, resulting in better tumor killing.</p><p id="__p34">The employment of imiquimod for tumor treatment has significant potential for clinical translation. Currently there is one ongoing phase I trial to assess the immunogenicity, safety, tolerability and efficacy of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine [<a href="#CR28" rid="CR28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394836">28</a>] followed by a booster vaccination with a recombinant vaccinia expressing HPV-16/18 E6 and E7 (TA-HPV) [<a href="#CR29" rid="CR29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845394839">29</a>] in combination with locally applied TLR7 agonist, imiquimod in patients with HPV-16+ high grade cervical intraepithelial neoplasia (CIN3) http://www.clinicaltrial.gov/ct2/show/<a id="__tag_845394845" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00788164" ref="reftype=extlink-clinical-trial&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00788164","term_id":"NCT00788164"}}</span>NCT00788164</a>. The application of imiquimod may generate local inflammation in the local lesional microenvironment, thus allowing the localized immune effector cells to access lesional epithelium in patients with CIN lesions, and function in tumor destruction in the local microenvironment.</p><p id="__p35" class="p p-last">In summary, our study demonstrates that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist, imiquimod enhances the antitumor immunity induced by DNA vaccination. Our study serves as an important foundation for future clinical translation.</p></div><div id="idm139868975845824" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139868975845824title">Acknowledgements</h2><div class="sec"><p id="__p46">This work was supported by 1 RO1 CA114425 01 and SPORE programs (P50 CA098252 and P50 CA96784-06) of the National Cancer Institute.</p></div></div><div id="App1" class="tsec sec headless whole_rhythm"><!--/article/back/app-group/app/--><div id="Sec16" class="sec sec-first"><h3 id="Sec16title">Authors&#x02019; original submitted files for images</h3><p id="__p36" class="p p-first-last">Below are the links to the authors&#x02019; original submitted files for images.<span class="sup-box" id="MOESM1"><a href="/pmc/articles/PMC2873498/bin/12929_2010_146_MOESM1_ESM.jpeg" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 1</a><sup>(91K, jpeg)</sup></span><span class="sup-box" id="MOESM2"><a href="/pmc/articles/PMC2873498/bin/12929_2010_146_MOESM2_ESM.jpeg" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 2</a><sup>(62K, jpeg)</sup></span><span class="sup-box" id="MOESM3"><a href="/pmc/articles/PMC2873498/bin/12929_2010_146_MOESM3_ESM.jpeg" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 3</a><sup>(48K, jpeg)</sup></span><span class="sup-box" id="MOESM4"><a href="/pmc/articles/PMC2873498/bin/12929_2010_146_MOESM4_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 4</a><sup>(78K, pdf)</sup></span><span class="sup-box" id="MOESM5"><a href="/pmc/articles/PMC2873498/bin/12929_2010_146_MOESM5_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 5</a><sup>(49K, pdf)</sup></span></p></div></div><div id="idm139868975848928" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139868975848928title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139868975848800"><p id="__p42" class="p p-first"><strong>Competing interests</strong></p><p id="__p43" class="p p-last">The authors declare that they have no competing interests.</p></p><p class="fn sec" id="idm139868975847376"><p id="__p44" class="p p-first"><strong>Authors\' contributions</strong></p><p id="__p45" class="p p-last">CMC was involved in the execution of the project. AM was involved in the interpretation of the data and writing the manuscript. CFH and TCW provided overall supervision and guidance for the project. All authors read and approved the manuscript.</p></p></div></div><div id="idm139869044196848aff-info" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139869044196848aff-infotitle">Contributor Information</h2><p><span class="fm-affl">Chi-Mu Chuang, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.oohay@gnaujmc" class="oemail">moc.oohay@gnaujmc</a></span>.</p><p><span class="fm-affl">Archana Monie, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.imhj@1einoma" class="oemail">ude.imhj@1einoma</a></span>.</p><p><span class="fm-affl">Chien-Fu Hung, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.imhj@2gnuhc" class="oemail">ude.imhj@2gnuhc</a></span>.</p><p><span class="fm-affl">T-C Wu, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.imhj@ctuw" class="oemail">ude.imhj@ctuw</a></span>.</p></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Meer DM Berends-van der, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Burg SH van der, Melief CJ. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. <span><span class="ref-journal">The New England journal of medicine. </span>2009;<span class="ref-vol">361</span>:1838\xe2\x80\x931847. doi: 10.1056/NEJMoa0810097.</span> [<a href="/pubmed/19890126" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMoa0810097" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+New+England+journal+of+medicine&amp;title=Vaccination+against+HPV-16+oncoproteins+for+vulvar+intraepithelial+neoplasia&amp;author=GG+Kenter&amp;author=MJ+Welters&amp;author=AR+Valentijn&amp;author=MJ+Lowik&amp;author=DM+Berends-van+der+Meer&amp;volume=361&amp;publication_year=2009&amp;pages=1838-1847&amp;pmid=19890126&amp;doi=10.1056/NEJMoa0810097&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="element-citation">Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. <span><span class="ref-journal">Life sciences. </span>1997;<span class="ref-vol">60</span>:163\xe2\x80\x93172. doi: 10.1016/S0024-3205(96)00502-4.</span> [<a href="/pubmed/9000640" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0024-3205(96)00502-4" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Life+sciences&amp;title=DNA+vaccines&amp;author=JJ+Donnelly&amp;author=JB+Ulmer&amp;author=MA+Liu&amp;volume=60&amp;publication_year=1997&amp;pages=163-172&amp;pmid=9000640&amp;doi=10.1016/S0024-3205(96)00502-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. <span><span class="ref-journal">Annual review of immunology. </span>2000;<span class="ref-vol">18</span>:927\xe2\x80\x93974. doi: 10.1146/annurev.immunol.18.1.927.</span> [<a href="/pubmed/10837079" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1146%2Fannurev.immunol.18.1.927" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annual+review+of+immunology&amp;title=DNA+vaccines:+immunology,+application,+and+optimization&amp;author=S+Gurunathan&amp;author=DM+Klinman&amp;author=RA+Seder&amp;volume=18&amp;publication_year=2000&amp;pages=927-974&amp;pmid=10837079&amp;doi=10.1146/annurev.immunol.18.1.927&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Hung CF, Wu TC. Improving DNA vaccine potency via modification of professional antigen presenting cells. <span><span class="ref-journal">Current opinion in molecular therapeutics. </span>2003;<span class="ref-vol">5</span>:20\xe2\x80\x9324.</span> [<a href="/pubmed/12669466" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Current+opinion+in+molecular+therapeutics&amp;title=Improving+DNA+vaccine+potency+via+modification+of+professional+antigen+presenting+cells&amp;author=CF+Hung&amp;author=TC+Wu&amp;volume=5&amp;publication_year=2003&amp;pages=20-24&amp;pmid=12669466&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Tsen SW, Paik AH, Hung CF, Wu TC. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. <span><span class="ref-journal">Expert review of vaccines. </span>2007;<span class="ref-vol">6</span>:227\xe2\x80\x93239. doi: 10.1586/14760584.6.2.227.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3190226/">PMC free article</a>]</span> [<a href="/pubmed/17408372" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1586%2F14760584.6.2.227" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+review+of+vaccines&amp;title=Enhancing+DNA+vaccine+potency+by+modifying+the+properties+of+antigen-presenting+cells&amp;author=SW+Tsen&amp;author=AH+Paik&amp;author=CF+Hung&amp;author=TC+Wu&amp;volume=6&amp;publication_year=2007&amp;pages=227-239&amp;pmid=17408372&amp;doi=10.1586/14760584.6.2.227&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="element-citation">Gelebart P, Opas M, Michalak M. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. <span><span class="ref-journal">The international journal of biochemistry &#x00026; cell biology. </span>2005;<span class="ref-vol">37</span>:260\xe2\x80\x93266. doi: 10.1016/j.biocel.2004.02.030.</span> [<a href="/pubmed/15474971" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.biocel.2004.02.030" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+international+journal+of+biochemistry+&#x00026;+cell+biology&amp;title=Calreticulin,+a+Ca2+-binding+chaperone+of+the+endoplasmic+reticulum&amp;author=P+Gelebart&amp;author=M+Opas&amp;author=M+Michalak&amp;volume=37&amp;publication_year=2005&amp;pages=260-266&amp;pmid=15474971&amp;doi=10.1016/j.biocel.2004.02.030&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. <span><span class="ref-journal">The Journal of clinical investigation. </span>2001;<span class="ref-vol">108</span>:669\xe2\x80\x93678. doi: 10.1172/JCI200112346.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC209378/">PMC free article</a>]</span> [<a href="/pubmed/11544272" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1172%2FJCI200112346" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+clinical+investigation&amp;title=Tumor-specific+immunity+and+antiangiogenesis+generated+by+a+DNA+vaccine+encoding+calreticulin+linked+to+a+tumor+antigen&amp;author=WF+Cheng&amp;author=CF+Hung&amp;author=CY+Chai&amp;author=KF+Hsu&amp;author=L+He&amp;volume=108&amp;publication_year=2001&amp;pages=669-678&amp;pmid=11544272&amp;doi=10.1172/JCI200112346&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="element-citation">Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC. Comparison of HPV DNA vaccines employing intracellular targeting strategies. <span><span class="ref-journal">Gene therapy. </span>2004;<span class="ref-vol">11</span>:1011\xe2\x80\x931018. doi: 10.1038/sj.gt.3302252.</span> [<a href="/pubmed/14985791" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fsj.gt.3302252" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gene+therapy&amp;title=Comparison+of+HPV+DNA+vaccines+employing+intracellular+targeting+strategies&amp;author=JW+Kim&amp;author=CF+Hung&amp;author=J+Juang&amp;author=L+He&amp;author=TW+Kim&amp;volume=11&amp;publication_year=2004&amp;pages=1011-1018&amp;pmid=14985791&amp;doi=10.1038/sj.gt.3302252&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:8468\xe2\x80\x938476. doi: 10.1128/JVI.78.16.8468-8476.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC479075/">PMC free article</a>]</span> [<a href="/pubmed/15280455" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.16.8468-8476.2004" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Development+of+a+DNA+vaccine+targeting+human+papillomavirus+type+16+oncoprotein+E6&amp;author=S+Peng&amp;author=H+Ji&amp;author=C+Trimble&amp;author=L+He&amp;author=YC+Tsai&amp;volume=78&amp;publication_year=2004&amp;pages=8468-8476&amp;pmid=15280455&amp;doi=10.1128/JVI.78.16.8468-8476.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, Viscidi R, Tsai YC, He L, Chen PJ, Boyd DA, Wu TC. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:4638\xe2\x80\x934645. doi: 10.1128/JVI.78.9.4638-4645.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC387705/">PMC free article</a>]</span> [<a href="/pubmed/15078946" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.9.4638-4645.2004" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Generation+and+characterization+of+DNA+vaccines+targeting+the+nucleocapsid+protein+of+severe+acute+respiratory+syndrome+coronavirus&amp;author=TW+Kim&amp;author=JH+Lee&amp;author=CF+Hung&amp;author=S+Peng&amp;author=R+Roden&amp;volume=78&amp;publication_year=2004&amp;pages=4638-4645&amp;pmid=15078946&amp;doi=10.1128/JVI.78.9.4638-4645.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. <span><span class="ref-journal">J Drugs Dermatol. </span>2009;<span class="ref-vol">8</span>:467\xe2\x80\x93474.</span> [<a href="/pubmed/19537370" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Drugs+Dermatol&amp;title=Beyond+a+decade+of+5%+imiquimod+topical+therapy&amp;author=A+Gaspari&amp;author=SK+Tyring&amp;author=T+Rosen&amp;volume=8&amp;publication_year=2009&amp;pages=467-474&amp;pmid=19537370&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Novak N, Yu CF, Bieber T, Allam JP. Toll-like receptor 7 agonists and skin. <span><span class="ref-journal">Drug news &#x00026; perspectives. </span>2008;<span class="ref-vol">21</span>:158\xe2\x80\x93165.</span> [<a href="/pubmed/18560614" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+news+&#x00026;+perspectives&amp;title=Toll-like+receptor+7+agonists+and+skin&amp;author=N+Novak&amp;author=CF+Yu&amp;author=T+Bieber&amp;author=JP+Allam&amp;volume=21&amp;publication_year=2008&amp;pages=158-165&amp;pmid=18560614&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. <span><span class="ref-journal">Nature immunology. </span>2002;<span class="ref-vol">3</span>:196\xe2\x80\x93200. doi: 10.1038/ni758.</span> [<a href="/pubmed/11812998" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fni758" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+immunology&amp;title=Small+anti-viral+compounds+activate+immune+cells+via+the+TLR7+MyD88-dependent+signaling+pathway&amp;author=H+Hemmi&amp;author=T+Kaisho&amp;author=O+Takeuchi&amp;author=S+Sato&amp;author=H+Sanjo&amp;volume=3&amp;publication_year=2002&amp;pages=196-200&amp;pmid=11812998&amp;doi=10.1038/ni758&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. <span><span class="ref-journal">Drug news &#x00026; perspectives. </span>2008;<span class="ref-vol">21</span>:69\xe2\x80\x9387. doi: 10.1358/dnp.2008.21.2.1188193.</span> [<a href="/pubmed/18389099" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1358%2Fdnp.2008.21.2.1188193" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+news+&#x00026;+perspectives&amp;title=The+antiviral+activity+of+Toll-like+receptor+7+and+7/8+agonists&amp;author=RL+Miller&amp;author=TC+Meng&amp;author=MA+Tomai&amp;volume=21&amp;publication_year=2008&amp;pages=69-87&amp;pmid=18389099&amp;doi=10.1358/dnp.2008.21.2.1188193&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Bilu D, Sauder DN. Imiquimod: modes of action. <span><span class="ref-journal">The British journal of dermatology. </span>2003;<span class="ref-vol">149</span>(Suppl 66):5\xe2\x80\x938.</span> [<a href="/pubmed/14616337" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+British+journal+of+dermatology&amp;title=Imiquimod:+modes+of+action&amp;author=D+Bilu&amp;author=DN+Sauder&amp;volume=149&amp;issue=Suppl+66&amp;publication_year=2003&amp;pages=5-8&amp;pmid=14616337&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. <span><span class="ref-journal">International journal of immunopharmacology. </span>1999;<span class="ref-vol">21</span>:1\xe2\x80\x9314. doi: 10.1016/S0192-0561(98)00068-X.</span> [<a href="/pubmed/10411278" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0192-0561(98)00068-X" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+journal+of+immunopharmacology&amp;title=Imiquimod+applied+topically:+a+novel+immune+response+modifier+and+new+class+of+drug&amp;author=RL+Miller&amp;author=JF+Gerster&amp;author=ML+Owens&amp;author=HB+Slade&amp;author=MA+Tomai&amp;volume=21&amp;publication_year=1999&amp;pages=1-14&amp;pmid=10411278&amp;doi=10.1016/S0192-0561(98)00068-X&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Lin KY, Guarnieri FG, Staveley-O\'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. <span><span class="ref-journal">Cancer research. </span>1996;<span class="ref-vol">56</span>:21\xe2\x80\x9326.</span> [<a href="/pubmed/8548765" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+research&amp;title=Treatment+of+established+tumors+with+a+novel+vaccine+that+enhances+major+histocompatibility+class+II+presentation+of+tumor+antigen&amp;author=KY+Lin&amp;author=FG+Guarnieri&amp;author=KF+Staveley-O\'Carroll&amp;author=HI+Levitsky&amp;author=JT+August&amp;volume=56&amp;publication_year=1996&amp;pages=21-26&amp;pmid=8548765&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="element-citation">Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. <span><span class="ref-journal">Vaccine. </span>2003;<span class="ref-vol">21</span>:4036\xe2\x80\x934042. doi: 10.1016/S0264-410X(03)00275-5.</span> [<a href="/pubmed/12922140" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0264-410X(03)00275-5" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Comparison+of+the+CD8++T+cell+responses+and+antitumor+effects+generated+by+DNA+vaccine+administered+through+gene+gun,+biojector,+and+syringe&amp;author=C+Trimble&amp;author=CT+Lin&amp;author=CF+Hung&amp;author=S+Pai&amp;author=J+Juang&amp;volume=21&amp;publication_year=2003&amp;pages=4036-4042&amp;pmid=12922140&amp;doi=10.1016/S0264-410X(03)00275-5&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. <span><span class="ref-journal">Cancer research. </span>2000;<span class="ref-vol">60</span>:1035\xe2\x80\x931042.</span> [<a href="/pubmed/10706121" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+research&amp;title=Enhancement+of+DNA+vaccine+potency+by+linkage+of+antigen+gene+to+an+HSP70+gene&amp;author=CH+Chen&amp;author=TL+Wang&amp;author=CF+Hung&amp;author=Y+Yang&amp;author=RA+Young&amp;volume=60&amp;publication_year=2000&amp;pages=1035-1042&amp;pmid=10706121&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. <span><span class="ref-journal">British journal of cancer. </span>2010;<span class="ref-vol">102</span>:1129\xe2\x80\x9336. doi: 10.1038/sj.bjc.6605611.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2853099/">PMC free article</a>]</span> [<a href="/pubmed/20234368" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fsj.bjc.6605611" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+journal+of+cancer&amp;title=Phase+II+trial+of+imiquimod+and+HPV+therapeutic+vaccination+in+patients+with+vulval+intraepithelial+neoplasia&amp;author=S+Daayana&amp;author=E+Elkord&amp;author=U+Winters&amp;author=M+Pawlita&amp;author=R+Roden&amp;volume=102&amp;publication_year=2010&amp;pages=1129-36&amp;pmid=20234368&amp;doi=10.1038/sj.bjc.6605611&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. <span><span class="ref-journal">Trends in immunology. </span>2002;<span class="ref-vol">23</span>:549\xe2\x80\x93555. doi: 10.1016/S1471-4906(02)02302-5.</span> [<a href="/pubmed/12401408" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1471-4906(02)02302-5" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Trends+in+immunology&amp;title=Macrophage+polarization:+tumor-associated+macrophages+as+a+paradigm+for+polarized+M2+mononuclear+phagocytes&amp;author=A+Mantovani&amp;author=S+Sozzani&amp;author=M+Locati&amp;author=P+Allavena&amp;author=A+Sica&amp;volume=23&amp;publication_year=2002&amp;pages=549-555&amp;pmid=12401408&amp;doi=10.1016/S1471-4906(02)02302-5&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. <span><span class="ref-journal">Front Biosci. </span>2008;<span class="ref-vol">13</span>:453\xe2\x80\x93461. doi: 10.2741/2692.</span> [<a href="/pubmed/17981560" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.2741%2F2692" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front+Biosci&amp;title=Macrophage+activation+and+polarization&amp;author=FO+Martinez&amp;author=A+Sica&amp;author=A+Mantovani&amp;author=M+Locati&amp;volume=13&amp;publication_year=2008&amp;pages=453-461&amp;pmid=17981560&amp;doi=10.2741/2692&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. <span><span class="ref-journal">Clin Cancer Res. </span>2009;<span class="ref-vol">15</span>:4391\xe2\x80\x934400. doi: 10.1158/1078-0432.CCR-09-0489.</span> [<a href="/pubmed/19549768" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1158%2F1078-0432.CCR-09-0489" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=HPV16+tumor+associated+macrophages+suppress+antitumor+T+cell+responses&amp;author=AP+Lepique&amp;author=KR+Daghastanli&amp;author=IM+Cuccovia&amp;author=LL+Villa&amp;volume=15&amp;publication_year=2009&amp;pages=4391-4400&amp;pmid=19549768&amp;doi=10.1158/1078-0432.CCR-09-0489&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="element-citation">Hart OM, Athie-Morales V, O\'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. <span><span class="ref-journal">J Immunol. </span>2005;<span class="ref-vol">175</span>:1636\xe2\x80\x931642. doi: 10.4049/jimmunol.175.3.1636.</span> [<a href="/pubmed/16034103" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.4049%2Fjimmunol.175.3.1636" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=TLR7/8-mediated+activation+of+human+NK+cells+results+in+accessory+cell-dependent+IFN-gamma+production&amp;author=OM+Hart&amp;author=V+Athie-Morales&amp;author=GM+O\'Connor&amp;author=CM+Gardiner&amp;volume=175&amp;publication_year=2005&amp;pages=1636-1642&amp;pmid=16034103&amp;doi=10.4049/jimmunol.175.3.1636&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. <span><span class="ref-journal">J Immunol. </span>2009;<span class="ref-vol">182</span>:4499\xe2\x80\x934506. doi: 10.4049/jimmunol.0802740.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2810498/">PMC free article</a>]</span> [<a href="/pubmed/19342621" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.4049%2Fjimmunol.0802740" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Myeloid-derived+suppressor+cells:+linking+inflammation+and+cancer&amp;author=S+Ostrand-Rosenberg&amp;author=P+Sinha&amp;volume=182&amp;publication_year=2009&amp;pages=4499-4506&amp;pmid=19342621&amp;doi=10.4049/jimmunol.0802740&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. <span><span class="ref-journal">Cancer letters. </span>2008;<span class="ref-vol">267</span>:216\xe2\x80\x93225. doi: 10.1016/j.canlet.2008.03.012.</span> [<a href="/pubmed/18433992" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.canlet.2008.03.012" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+letters&amp;title=Myeloid-derived+suppressor+cell+role+in+tumor-related+inflammation&amp;author=L+Dolcetti&amp;author=I+Marigo&amp;author=B+Mantelli&amp;author=E+Peranzoni&amp;author=P+Zanovello&amp;volume=267&amp;publication_year=2008&amp;pages=216-225&amp;pmid=18433992&amp;doi=10.1016/j.canlet.2008.03.012&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR27">27. <span class="element-citation">Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. <span><span class="ref-journal">Immunological reviews. </span>2008;<span class="ref-vol">222</span>:162\xe2\x80\x93179. doi: 10.1111/j.1600-065X.2008.00602.x.</span> [<a href="/pubmed/18364001" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1111%2Fj.1600-065X.2008.00602.x" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+reviews&amp;title=Tumor-induced+tolerance+and+immune+suppression+by+myeloid+derived+suppressor+cells&amp;author=I+Marigo&amp;author=L+Dolcetti&amp;author=P+Serafini&amp;author=P+Zanovello&amp;author=V+Bronte&amp;volume=222&amp;publication_year=2008&amp;pages=162-179&amp;pmid=18364001&amp;doi=10.1111/j.1600-065X.2008.00602.x&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR28">28. <span class="element-citation">Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. <span><span class="ref-journal">Clin Cancer Res. </span>2009;<span class="ref-vol">15</span>:361\xe2\x80\x93367. doi: 10.1158/1078-0432.CCR-08-1725.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2865676/">PMC free article</a>]</span> [<a href="/pubmed/19118066" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1158%2F1078-0432.CCR-08-1725" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=A+phase+I+trial+of+a+human+papillomavirus+DNA+vaccine+for+HPV16++cervical+intraepithelial+neoplasia+2/3&amp;author=CL+Trimble&amp;author=S+Peng&amp;author=F+Kos&amp;author=P+Gravitt&amp;author=R+Viscidi&amp;volume=15&amp;publication_year=2009&amp;pages=361-367&amp;pmid=19118066&amp;doi=10.1158/1078-0432.CCR-08-1725&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR29">29. <span class="element-citation">Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. <span><span class="ref-journal">Clin Cancer Res. </span>3685;<span class="ref-vol">8</span>:3676\xe2\x80\x932002.</span> [<a href="/pubmed/12473576" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Safety+and+immunogenicity+of+TA-HPV,+a+recombinant+vaccinia+virus+expressing+modified+human+papillomavirus+(HPV)-16+and+HPV-18+E6+and+E7+genes,+in+women+with+progressive+cervical+cancer&amp;author=AM+Kaufmann&amp;author=PL+Stern&amp;author=EM+Rankin&amp;author=H+Sommer&amp;author=V+Nuessler&amp;volume=8&amp;publication_year=3685&amp;pages=3676-2002&amp;pmid=12473576&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2873498&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2873498/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2873498/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2873498/pdf/12929_2010_Article_146.pdf">PDF (2.7M)</a></li> | <li><a href="#" data-citationid="PMC2873498" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2873498%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2873498%2F&amp;text=Treatment%20with%20Imiquimod%20enhances%20antitumor%20immunity%20induced%20by%20therapeutic%20HPV%20DNA%20vaccination"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2873498%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="20426849" data-aiid="7100746" data-aid="2873498" data-iid="354895" data-domainid="3814" data-domain="phenaturepg" data-accid="PMC2873498" data-md5="db4a5db572c6dbfcf6a908730799081c"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:39:30-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc101&amp;ncbi_phid=8A1A0F6CE9A4031100000000059D059A&amp;ncbi_session=8A1A0F6CE9A4C411_1437SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2873498%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=phenaturepg&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2873498/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1A0F6CE9A4C411_1437SID /projects/PMC/PMCViewer@4.46 ptpmc101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'